Clinical Trial Update: A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study comparing HSP-130 with US- and EU-approved Neulasta (pegfilgrastim) in healthy participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• HSP-130
• NEULASTA (pegfilgrastim)

Snippet

Sponsor: Pfizer | Conditions: Neutropenia | Phase 1 | Status: COMPLETED